{"disease":{"id":"camrelizumab","name":"camrelizumab"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05475678","title":"Clinical Study of Camrelizumab Combined With TCb Versus TCb in Neoadjuvant Treatment of Triple-negative Breast Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":369,"lead_sponsor_name":"Zhenzhen Liu","has_results":false},{"nct_id":"NCT06276933","title":"A Study of Camrelizumab Combined With Chemotherapy ± Thalidomide in First-line Treatment of Patients With Advanced Non-small Cell Lung Cancer (NSCLC)","phase":"PHASE4","overall_status":"NOT_YET_RECRUITING","enrollment_count":104,"lead_sponsor_name":"Tongji University","has_results":false},{"nct_id":"NCT06485466","title":"TACE Plus Camrelizumab and Apatinib for Unresectable Hepatocellular Carcinoma","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":101,"lead_sponsor_name":"Guohui Xu","has_results":false},{"nct_id":"NCT05512481","title":"Camrelizumab Plus Apatinib and Temozolomide as Neoadjuvant in High Risk Acral Melanoma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"Peking University Cancer Hospital & Institute","has_results":false},{"nct_id":"NCT05114707","title":"Camrelizumab Plus Chemoradiotherapy for Patients With Locoregional Cancer of Nasal Cavity and Paranasal Sinuses","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":57,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT04889768","title":"HIPEC Combined With Camrelizumab, Paclitaxel and S-1 for Conversion Therapy in Patients With Advanced Gastric Cancer With Peritoneal Metastasis","phase":"NA","overall_status":"UNKNOWN","enrollment_count":46,"lead_sponsor_name":"Zhejiang Cancer Hospital","has_results":false},{"nct_id":"NCT05170542","title":"The Neoadjuvant Treatment of Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma.","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":42,"lead_sponsor_name":"Peking Union Medical College Hospital","has_results":false},{"nct_id":"NCT06061276","title":"bTAE-HAIC Combined With System Therapy for Intermediate-advanced Huge HCC","phase":"NA","overall_status":"RECRUITING","enrollment_count":40,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT03919539","title":"Epigenetic Biomarker for Advanced Osteosarcoma Using Famitinib and Camrelizumab","phase":"","overall_status":"UNKNOWN","enrollment_count":40,"lead_sponsor_name":"Peking University People's Hospital","has_results":false}],"total":9},"guidelines":[],"source":"Drug Landscape verified database"}